Novel materials, adjuvants, targeting strategies, and controlled release mechanisms are overcoming the barriers that have limited peptide cancer vaccine effectiveness against cold tumors.
Overcoming cold tumorsNew peptide vaccine platforms could prime immune responses in cancers that currently resist checkpoint immunotherapy
What the researchers found
Novel platforms for peptide cancer vaccines using advanced materials, adjuvants, targeting, and controlled release are overcoming barriers of immune tolerance, poor delivery, and immunosuppressive microenvironment.
Why it matters
Immune checkpoint drugs work for only a subset of patients. Peptide vaccines could prime the immune system to respond to these drugs, expanding their benefit to many more cancer patients.
How the study worked
Review of recent advances in peptide-based cancer vaccine design, covering materials, adjuvants, targeting strategies, controlled release, and clinical translation.
What this study cannot tell us
Many platforms still in preclinical stages. Personalized neoantigen vaccines are expensive. Cold tumor conversion remains challenging.
How to read the evidence
Comprehensive review of primarily preclinical advances with some clinical data.
When this study was published
Published in 2025.
The bigger picture
Peptide cancer vaccines represent the next frontier for expanding immunotherapy beyond currently responsive tumors to the majority of cancers that resist checkpoint drugs.
Questions still open
- Which delivery platform will prove most effective in clinical trials?
- Can off-the-shelf peptide vaccines replace personalized neoantigen approaches?
- How should peptide vaccines be combined with checkpoint inhibitors?
Common questions
What are peptide cancer vaccines?
Why haven't peptide cancer vaccines worked well so far?
Read the original research
Advances in Peptide-Based Cancer Vaccines: Materials, Targeting, and Delivery Strategies.
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 18(1), e70044
Citation
Garland, Shea; Lux, Jacques. (2026). Advances in Peptide-Based Cancer Vaccines: Materials, Targeting, and Delivery Strategies.. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 18(1), e70044. https://doi.org/10.1002/wnan.70044